Microsatellite instability (MSI) is a tumor molecular phenotype that evolves from loss of
function in the mismatch repair (MMR) proteins through deleterious germline mutations …

In the last decades, the development of high‐throughput molecular assays has
revolutionised cancer diagnostics, paving the way for the concept of personalised cancer …

Mismatch repair deficiency (MMR-D) has become a theragnostic marker to guide treatment
with immune checkpoint inhibitors (ICIs) for patients at all stages of cancer and with a …

Mismatch repair deficiency (MMR-d) and microsatellite instability (MSI) are prognostic and
predictive biomarkers. Current testing for MMR/MSI relies on immunohistochemistry (IHC) for …

Microsatellite instability high (MSI-H) and mismatch repair deficient (dMMR) tumor status
have been demonstrated to predict patient response to immunotherapies. We developed …

Background Immunohistochemistry (IHC) and traditional polymerase chain reaction (PCR)
are the methods of choice in clinical practice to identify the mismatch repair (MMR) and …

Mismatch repair (MMR) testing on all new cases of colorectal cancer (CRC) has customarily
been preferably performed on surgical specimens, as more tissue is available; however …

Background Lynch syndrome (LS) is under-diagnosed. UK National Institute for Health and
Care Excellence guidelines recommend multistep molecular testing of all colorectal cancers …

PURPOSE The pan-cancer presence of microsatellite instability (MSI)–positive tumors
demonstrates its clinical utility as an agnostic biomarker for identifying immunotherapy …

Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes across several solid
tumour types. Prominent efforts have focused on understanding the anticancer mechanisms …